XERS Crosses Below Key Moving Average Level
Shares of Xeris Biopharma Holdings Inc (XERS) have fallen below their 200-day moving average of $6.76, trading as low as $6.41 per share on Thursday. This represents a drop of about 6.5% on the day. The article notes that XERS's 52-week trading range is between $3.58 and $10.08, with the last trade at $6.55.
Xeris Biopharma Holdings, Inc. $XERS Shares Sold by CenterBook Partners LP
CenterBook Partners LP significantly reduced its stake in Xeris Biopharma Holdings, Inc. ($XERS) during the third quarter, selling over 896,000 shares. Despite this, analysts have a "Moderate Buy" consensus rating for XERS with a target price of $10.08, and the stock received a price target increase from Piper Sandler and a new "overweight" rating from Barclays. Insiders have also been net sellers of the stock recently, while institutional investors and hedge funds collectively own 42.75% of the company.
Will Xeris Stock Revisit Its 52-week High?
Xeris Biopharma Holdings Inc. (XERS) entered 2026 with strong commercial momentum after a transformative 2025, driven by its products Recorlev, Gvoke, and Keveyis. The company's product revenue has shown sustained growth, reaching $196.64 million in 2024. Investors are awaiting the full-year 2025 results, with anticipated total revenue of $292 million, following a significant rally in its stock price to a 52-week high of $10.08 in November 2025.
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026
Xeris Biopharma Holdings, Inc. announced it will release its fourth quarter and full-year 2025 financial results on Monday, March 2, 2026, before the U.S. financial markets open. Management will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the financial and operational results for the year 2025 and provide guidance for 2026. Interested parties can pre-register for the call or join the live webcast via provided links, with a replay available on the company's Investor Relations website.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from Analysts
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has received an average "Moderate Buy" rating from eight analysts, with a 12-month average target price of $10.08. Despite recent insider selling totaling over $2 million, institutional investors, including Vanguard and UBS, have been increasing their positions, resulting in 42.75% institutional ownership. The company, focused on endocrine and orphan diseases, trades near $7.01 with a $1.16 billion market cap.
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Institutional Investors Lost 4.6% Over the Past Week but Have Profited From Longer-term Gains
Institutional investors in Xeris Biopharma Holdings (NASDAQ:XERS) experienced a 4.6% loss last week, though they have seen a 91% return over the past year. Institutions hold a 60% stake in the company, making its stock price vulnerable to their trading decisions. While insider ownership is positive, it's noted that top shareholders collectively own less than 50%, with no single individual having a majority interest.
How Xeris’ Diversified Product Portfolio and XP-8121 Progress Could Shape Xeris Biopharma (XERS) Investors
Xeris Biopharma Holdings is gaining investor and analyst interest due to its commercial therapies Gvoke, Keveyis, and Recorlev, as well as its phase 3 candidate XP-8121 for hypothyroidism. This diversified product portfolio positions Xeris as a multi-asset biopharma platform rather than a single-drug company. While the share price hasn't seen a significant jump yet, XP-8121's progress and upcoming earnings (March 2, 2026) are key factors influencing sentiment, despite risks like unprofitability and negative equity.
How Xeris’ Diversified Product Portfolio and XP-8121 Progress Could Shape Xeris Biopharma (XERS) Investors
Xeris Biopharma is gaining investor and analyst interest due to its diversified portfolio of commercial therapies (Gvoke, Keveyis, Recorlev) and its phase 3 candidate XP-8121 for hypothyroidism. This combination is shaping perceptions of Xeris as a multi-asset biopharma platform rather than a single-drug company. While the share price hasn't seen a significant step change yet, XP-8121 is considered a key factor for future sentiment, despite existing risks such as the company's unprofitable status and negative equity.
Y Intercept Hong Kong Ltd Lowers Holdings in Xeris Biopharma Holdings, Inc. $XERS
Y Intercept Hong Kong Ltd significantly reduced its stake in Xeris Biopharma Holdings, Inc. during the third quarter, selling 254,033 shares and retaining 82,181 shares valued at $669,000. This move aligns with broader insider selling, as company insiders sold 280,217 shares worth $2.04 million, decreasing their ownership to 4.56%. Analysts currently maintain a "Moderate Buy" rating for Xeris Biopharma, with an average price target of $10.08, despite the company recently missing its quarterly EPS estimates.
Xeris Biopharma (NASDAQ:XERS) Insider Beth Hecht Sells 16,667 Shares
Xeris Biopharma insider Beth Hecht sold 16,667 shares of the company's stock on February 2, 2026, for approximately $124,169. This recent sale is part of a series of transactions, bringing her total sales to 66,668 shares worth roughly $488,176 since November, and reducing her stake by 1.32%. Despite the insider selling, analysts maintain a "Moderate Buy" rating for XERS with an average price target of $10.08, while hedge funds have been increasing their positions in the company.
Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: Unlocking a 53.91% Potential Upside in the Biotech Arena
Xeris Biopharma Holdings, Inc. (XERS) shows a promising 53.91% potential upside in the biotechnology sector, driven by strong revenue growth and a robust product pipeline including Gvoke, Keveyis, and Recorlev. Analysts maintain an overwhelmingly positive outlook with an average target price of $11.14, signaling significant growth potential despite current unprofitability. The company's diverse therapies for chronic endocrine and neurological diseases, coupled with a healthy free cash flow and bullish technical indicators, position it as an attractive high-reward opportunity for investors in biotech.
Does Xeris Biopharma (XERS) Boosted 2025 Revenue Guidance Strengthen Its Commercial Momentum Narrative?
Xeris Biopharma (XERS) recently raised its 2025 revenue guidance to approximately US$292 million, signaling stronger-than-expected commercial traction. While this supports the near-term revenue outlook, the company still faces risks from product concentration and external pressures. Analysts project significant revenue and earnings growth by 2028, but investor opinions on fair value vary widely, underscoring the divided expectations for its concentrated portfolio.
A Look At Xeris Biopharma Holdings (XERS) Valuation After Its Updated 2025 Revenue Outlook
Xeris Biopharma Holdings (XERS) has updated its 2025 revenue outlook to approximately US$292 million, an increase from its previous guidance. Despite recent short-term share price fluctuations, the company has shown strong long-term momentum. Analysts currently view XERS as undervalued, with a fair value of US$11.50, driven by the potential of its upcoming XP-8121 launch and proprietary delivery technology.
Does Xeris Biopharma (XERS) Boosted 2025 Revenue Guidance Strengthen Its Commercial Momentum Narrative?
Xeris Biopharma Holdings, Inc. recently raised its full-year 2025 revenue guidance to approximately US$292 million, indicating stronger commercial traction than anticipated. This update impacts the company's investment narrative, which relies on rapid scaling of its endocrine and neurological portfolio to overcome losses and balance sheet pressures. While the increased guidance supports near-term revenue prospects and implies a fair value of $11.50, investors should consider the concentrated nature of its revenue base and how specific events like the upcoming 2025 results release and analyst day will further shape its trajectory.
How Investors Are Reacting To Xeris Biopharma (XERS) Raising 2025 Revenue Outlook And Recorlev Momentum
Xeris Biopharma Holdings (XERS) recently raised its full-year 2025 revenue guidance to approximately US$292 million, citing strong fourth-quarter and full-year performance, and momentum for its drug Recorlev. This updated outlook reinforces Recorlev's role as a key growth driver, but the company's reliance on a narrow product portfolio presents a concentration risk. Despite diverse fair value estimates from analysts, Xeris Biopharma's long-term narrative projects significant revenue and earnings growth by 2028, with a potential 41% upside from its current price.
Is Xeris Biopharma Holdings (XERS) Price Rally Still Justified After Recent Company Updates
Xeris Biopharma Holdings (XERS) has seen significant price rallies, with the stock closing at US$7.93 and experiencing substantial returns over various periods. Despite recent company updates, a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued, estimating an intrinsic value of $41.67 per share. The company's Price/Sales (P/S) ratio of 4.94x is above the industry average, yet Simply Wall St's Fair Ratio indicates it is still undervalued at its current price.
XERS: HC Wainwright & Co. Reiterates Buy Rating with $10.00 Price Target
HC Wainwright & Co. has reiterated its Buy rating for Xeris Biopharma Holdings (XERS) with a consistent price target of $10.00, reflecting confidence in the company's prospects. This decision aligns with other analyst ratings, with the average target price from 7 analysts being $11.14, suggesting a 37.06% upside from the current price, despite GuruFocus's GF Value estimate indicating a potential downside. Xeris Biopharma specializes in developing therapies for chronic endocrine and neurological diseases.
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
Xeris Biopharma Holdings, Inc. announced preliminary unaudited financial results for Q4 and full-year 2025, projecting record total revenue of $292 million, surpassing previous guidance. This success is attributed to strong performances from Recorlev®, Gvoke®, and Keveyis®, with Recorlev® exceeding expectations and driving significant overall growth. The company anticipates continued commercial momentum and plans to release full financial results and its 2026 outlook in March 2026.
Xeris Biopharma expects full-year 2025 revenue above estimates
Xeris Biopharma expects its full-year 2025 revenue to exceed current estimates. This positive outlook suggests strong financial performance for the company in the upcoming year.
A biotech treating 700 patients is on track for a record revenue year
Xeris Biopharma (XERS) anticipates a record total revenue of $292 million for the full year 2025, exceeding its guidance range and representing a 44% growth year-over-year. This strong performance is attributed to the success of its products Recorlev®, Gvoke®, and Keveyis®, with Recorlev® specifically treating approximately 700 patients. The company also reported positive Adjusted EBITDA for every quarter and strengthened its intellectual property portfolio.
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
Xeris Biopharma Holdings, Inc. announced preliminary unaudited financial results for Q4 and full-year 2025, anticipating record total revenue of approximately $292 million, exceeding their guidance. This strong performance was driven by exceptional results from Recorlev®, Gvoke®, and Keveyis®. The company also highlighted strengthened intellectual property and a clear strategic vision for sustained growth.
Xeris Biopharma director Shannon sells $176k in shares By Investing.com
Xeris Biopharma director John Patrick Shannon Jr. sold 24,907 shares for $176,256 and exercised options for 92,201 shares totaling $149,997. The company, valued at $1.16 billion, has shown a 42.05% revenue growth and its stock is up 107.76% over the past year. Recent developments include regulatory obstacles for a competitor, a reiterated "Buy" rating from Jefferies, and a patent notice for a new hypothyroidism treatment.
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
Xeris Biopharma Holdings, Inc. announced preliminary unaudited financial results for the fourth quarter and fiscal year 2025, anticipating record total revenue of $292 million, exceeding guidance. This growth is driven by strong performance from its products Recorlev®, Gvoke®, and Keveyis®. The company also reported strengthening its intellectual property portfolio and achieving positive Adjusted EBITDA in every quarter of 2025.
Xeris Biopharma director Shannon sells $176k in shares By Investing.com
John Patrick Shannon Jr., a director at Xeris Biopharma Holdings Inc (NASDAQ:XERS), sold 24,907 shares for over $176,000 on January 5, 2026, while also exercising options to acquire 92,201 shares. The company has experienced significant revenue growth and stock performance, with analysts maintaining a Buy rating. Recent developments include a patent for hypothyroidism treatment and a potential market advantage due to a competitor's regulatory hurdle.
Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock
Beth Hecht, an insider at Xeris Biopharma (NASDAQ:XERS), sold 16,667 shares of the company's stock on January 2nd at an average price of $7.43, totaling $123,835.81. This sale reduced her position by 1.26%, leaving her with 1,308,103 shares. The company's stock traded down 3.5% to $7.09, and analysts have a "Moderate Buy" rating with an average target price of $9.50.
Xeris Biopharma Holdings, Inc. $XERS Shares Sold by Diversified Trust Co
Diversified Trust Co significantly reduced its stake in Xeris Biopharma Holdings, Inc. by 81.2% in Q3, selling over 138,000 shares. Despite this, other hedge funds increased their positions in the company, and insiders have been net sellers in the past 90 days. The stock trades around $7.35 with analysts holding a "Moderate Buy" consensus and a target price of $9.50.
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Biopharma Holdings, Inc. announced the granting of restricted stock units for 181,550 shares of its common stock to 50 new employees. These grants were made under Xeris’ Inducement Equity Plan, in accordance with NASDAQ Listing Rule 5635(c)(4), to incentivize new hires. The restricted stock units will vest over three years, contingent on continued employment.
Calamos Advisors LLC Makes New Investment in Xeris Biopharma Holdings, Inc. $XERS
Calamos Advisors LLC has made a new investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), purchasing 137,097 shares valued at approximately $1.12 million in the third quarter. Despite this new investment, Xeris Biopharma has experienced significant insider selling, with 206,976 shares sold by insiders in the last 90 days. The stock is currently rated a "Moderate Buy" by analysts with an average target price of $9.50, even after missing recent EPS estimates.
Is Xeris Biopharma on the Verge of a Breakthrough?
Xeris Biopharma Holdings Inc. (NASDAQ: XERS) has seen its stock trade up by 9.51% following successful clinical trial results and a Notice of Allowance for its XP-8121 patent in hypothyroidism treatment. Barclays initiated coverage with an Overweight rating and a $9 price target, while FactSet analysts generally rate it a "buy" with an average target of $11.14, indicating strong confidence in the company's strategic direction and growth prospects. Despite challenges like long-term debt and negative book values, the company's high gross margin and strategic patent bolster investor optimism.
Jefferies reiterates Buy rating on Xeris Pharmaceuticals stock amid competitor setback
Jefferies has reiterated a Buy rating and a $10.00 price target on Xeris Pharmaceuticals (NASDAQ:XERS) after a regulatory setback for competitor Corcept Therapeutics. The FDA issued a Complete Response Letter for Corcept’s relacorilant, which Jefferies views as positive for Xeris as it potentially delays a new competitor in the Cushing's market. Xeris plans to double its sales representatives for its Cushing’s treatment Recorlev, and current 2026 revenue estimates for Recorlev may be conservative due to the competitor's delay.
Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday
Xeris Biopharma's stock rose over 7% due to a setback experienced by its competitor, Corcept Therapeutics. The FDA declined to approve Corcept's drug, relacorilant, which would have competed with Xeris's Recorlev for treating Cushing's syndrome. An analyst from Jefferies reiterated a "buy" rating for Xeris, forecasting growth in the Cushing's disease market, further boosting investor confidence.
Investors Buy Large Volume of Call Options on Xeris Biopharma (NASDAQ:XERS)
Investors recently purchased an unusually large volume of call options for Xeris Biopharma (NASDAQ:XERS), with 2,121 call options traded, marking a 399% increase over the average daily volume. The stock performed well in mid-day trading, reaching $8.07. Despite mixed analyst ratings, the company holds an average "Moderate Buy" rating with an average target price of $9.50, although insiders have been net sellers, divesting over $1.5 million in shares over the past 90 days.
Jefferies reiterates Buy rating on Xeris Pharmaceuticals stock amid competitor setback
Jefferies has reiterated a Buy rating and $10.00 price target on Xeris Pharmaceuticals (NASDAQ:XERS) after competitor Corcept Therapeutics faced a regulatory setback for its drug relacorilant. This delay could remove a potential competitor from the growing Cushing's market, benefiting Xeris and potentially making its 2026 Recorlev revenue estimates conservative. Xeris is also advancing its investigational hypothyroidism treatment, XP-8121, with a new patent allowance.
Xeris Biopharma Holdings, Inc. $XERS Shares Acquired by Voya Investment Management LLC
Voya Investment Management LLC significantly increased its stake in Xeris Biopharma Holdings, Inc. ($XERS) during Q3, boosting its ownership by 866.6% to 400,079 shares valued at approximately $3.26 million. The company has a "Moderate Buy" consensus rating from analysts with an average price target of $9.50. Recent insider transactions show sales of 206,976 shares over the last 90 days, with insiders now owning 6.47% of the stock.
Have Xeris Biopharma Holdings Insiders Been Selling Stock?
An independent non-executive director at Xeris Biopharma Holdings recently sold a significant amount of stock, reducing their total holding by 17%. While this is the largest insider sale in the last year, insiders still own 4.3% of the company, indicating some alignment with shareholders. Despite some insider buying, the overall trend suggests caution due to more sales than purchases over the past year.
Squarepoint Ops LLC Purchases 268,572 Shares of Xeris Biopharma Holdings, Inc. $XERS
Squarepoint Ops LLC significantly increased its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by purchasing an additional 268,572 shares, bringing its total ownership to 284,567 shares valued at approximately $1.33 million. This comes amidst insider selling by key figures like Director John Johnson and mixed analyst ratings, with a consensus of "Moderate Buy" and an average price target of $9.50. The article also provides detailed financial performance and other institutional investor activities.
Have Xeris Biopharma Holdings Insiders Been Selling Stock?
An Independent Non-Executive Director at Xeris Biopharma Holdings recently sold US$977k worth of stock, reducing their holding by 17%. Over the last year, insiders have sold more shares than they bought, and while insiders own 4.3% of the company, the history of sales suggests a cautious outlook for potential investors.
Director John Johnson Sells 135,400 Shares of Xeris Biopharma Holdings Inc
Director John Johnson sold 135,400 shares of Xeris Biopharma Holdings Inc (XERS) on December 19, 2025. This transaction is part of a trend where Johnson has sold 242,900 shares over the past year without any purchases, and there have been 1 insider buy versus 10 insider sells for the company in the same period. The stock is considered significantly overvalued with a price-to-GF-Value ratio of 1.84, trading at $7.22 per share against an estimated GF Value of $3.92.
Director John Johnson Sells 135,400 Shares of Xeris Biopharma Ho
Director John Johnson sold 135,400 shares of Xeris Biopharma Holdings Inc (XERS) on December 19, 2025, reducing his total holdings to 698,083 shares. This transaction follows a pattern of insider selling for XERS, with 1 insider buy versus 10 insider sells over the past year. The stock is currently trading at $7.22, significantly above its GF Value of $3.92, indicating it may be overvalued.
Xeris Biopharma (NASDAQ:XERS) Director Sells $977,588.00 in Stock
Xeris Biopharma (NASDAQ:XERS) Director John Johnson sold 135,400 shares of the company's stock on December 19th for a total of $977,588. This transaction reduced his ownership by 16.25%, bringing his total direct holdings to 698,083 shares. The company's stock traded up by $0.33 during mid-day trading and holds a "Moderate Buy" consensus rating among analysts with an average target price of $9.50.
Xeris Biopharma Holdings, Inc. (XERS): A Bull Case Theory
This article summarizes a bullish thesis on Xeris Biopharma Holdings, Inc. (XERS), highlighting its transition to a profitable specialty pharma platform with strong revenue growth projected to exceed $360 million by 2026 and $900 million by 2028. The company benefits from a "cash-compounder flywheel," proprietary formulation platforms, and a niche commercial model, suggesting significant re-rating potential despite current operational risks.
Xeris Biopharma Holdings, Inc. (XERS): A Bull Case Theory
This article summarizes a bullish thesis on Xeris Biopharma Holdings, Inc. (XERS), highlighting its transition to a profitable specialty-pharma platform with expected revenues surpassing $360 million by 2026 and potentially $900 million by 2028. The company is poised for a re-rating given its current valuation, debt-free balance sheet, and robust pipeline, with price targets ranging from $17-18 to $25-28 per share. Xeris' competitive moat is built on proprietary formulation platforms, regulatory exclusivity, and a niche-focused commercial model designed to attract institutional capital and reduce the cost of equity.
Xeris Biopharma: A Balanced Perspective Needed (Rating Downgrade)
Xeris Biopharma's Q3 revenue grew by 37.9%, leading to raised 2025 guidance, yet its shares dropped 30% due to decelerating growth momentum. While gross margin improved to 85%, investor concerns arose from slowing Recorlev growth and increasing costs associated with Recorlev expansion and XP-8121 clinical trials. The author has downgraded XERS to a Hold, suggesting gradual accumulation on weakness due to lingering upside potential.
Insider Selling: Xeris Biopharma (NASDAQ:XERS) Director Sells 15,000 Shares of Stock
Xeris Biopharma (NASDAQ:XERS) Director Barbara-Jean Bormann-Kennedy sold 15,000 shares of the company's stock on December 12th at an average price of $7.09, totaling $106,350. This transaction reduced her holdings by 9.52% to 142,500 shares. Following this, XERS shares traded down by 1.7% to $7.05, despite maintaining a consensus "Moderate Buy" rating and an average price target of $9.50 from analysts.
Jump Financial LLC Raises Stock Position in Xeris Biopharma Holdings, Inc. $XERS
Jump Financial LLC significantly increased its stake in Xeris Biopharma Holdings, Inc. by 78.6% in the second quarter, now holding 756,403 shares valued at approximately $3.53 million. This increase is part of a broader trend of institutional investors adding positions, bringing institutional ownership to 42.75%, while company insiders have been net sellers. Analysts have assigned an average "Moderate Buy" rating for XERS with a $9.50 price target.
Walleye Capital LLC Sells 448,444 Shares of Xeris Biopharma Holdings, Inc. $XERS
Walleye Capital LLC significantly reduced its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by selling 448,444 shares, leaving it with 0.15% of the company. Despite this, several other institutions like Nuveen, Parkman Healthcare, Goldman Sachs, CenterBook, and Invesco increased their positions, with institutional and hedge fund ownership reaching 42.75%. The company recently missed EPS estimates but met revenue expectations, and analysts maintain a "Moderate Buy" rating with a $9.50 target.
561,700 Shares in Xeris Biopharma Holdings, Inc. $XERS Bought by Norges Bank
Norges Bank has initiated a new position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), acquiring 561,700 shares valued at approximately $2.62 million, representing about 0.35% of the company. Despite this institutional buying, company insiders have been net sellers, divesting over 56,000 shares in the past 90 days. Xeris Biopharma holds a "Moderate Buy" consensus rating from analysts with an average price target of $9.50, though it recently missed EPS expectations while exceeding revenue forecasts.
Xeris Biopharma (XERS): Valuation Check After USPTO Notice of Allowance for Weekly Levothyroxine XP-8121 Patent
Xeris Biopharma (XERS) received a USPTO Notice of Allowance for XP-8121, its weekly levothyroxine injection, boosting its stock significantly. Despite a strong stock performance and analyst targets suggesting undervaluation at $11.50, the company faces challenges including reliance on a narrow product lineup and rising operating costs. While the P/S ratio indicates the stock is slightly richer than the US pharma average, it's notably below peers, suggesting potential upside without being an extreme bargain.
Xeris Biopharma’s (XERS) Positioning Strengthens After Reaching Product Pipeline Milestone
Xeris Biopharma Holdings Inc. (NASDAQ:XERS) announced a significant pipeline milestone with the United States Patent and Trademark Office's (USPTO) issuance of a Notice of Allowance for its XP-8121 formulation. This once-a-week subcutaneous injection, developed using the XeriSol platform, aims to address variable absorption issues associated with existing oral levothyroxine. The company believes this patent strengthens its intellectual property for XP-8121, which targets an unmet medical need for hypothyroidism, and highlights the versatility of its XeriSol platform.
Xeris Biopharma’s (XERS) Positioning Strengthens After Reaching Product Pipeline Milestone
Xeris Biopharma (XERS) has strengthened its product pipeline with a Notice of Allowance from the USPTO for its XP-8121 formulation, a once-a-week subcutaneous injection utilizing the XeriSol platform for treating hypothyroidism. This patent is a crucial milestone, enhancing intellectual property protection and showcasing the versatility of their XeriSol platform. The company also markets three other medications: Recorlev, Gvoke, and Keveyis.
